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Abstract
Background: Nucleic acid amplification of the IS481 region by PCR is more sensitive than culture
for detection and diagnosis of Bordetella pertussis but the assay has known cross-reactivity for
Bordetella holmesii and its use as a routine diagnostic assay has not been widely evaluated.
Methods: The objectives of this study were: 1) to assess the diagnostic utility of real-time IS481
PCR by comparison of results with culture and direct fluorescent antigen (DFA) testing for B.
pertussis, 2) to employ a PCR assay designed against a different insertion sequence (IS1001) to
assess the incidence of B. holmesii in symptomatic individuals and 3) to design and evaluate a new
PCR-based assay which could be used for B. pertussis confirmation. A total of 808 nasopharyngeal
specimens were included in the study the majority of which were submitted in charcoal transport
medium (88%) with the rest submitted in Regan-Lowe medium.
Results: Concordant results for PCR, DFA and culture were obtained for 21 B. pertussis positive
and 729 B. pertussis negative specimens. DFA was prone to false positive and negative reactions
when compared with both PCR and culture. The IS481 PCR identified 28 positive results for
specimens that were DFA and culture negative. A novel real-time PCR targeting the B. pertussis
toxin promoter was found to be specific and useful for confirming the majority of IS481 positive
specimens as B. pertussis. B. holmesii was not detected in any of the submitted samples.
Conclusion:  The potential pick up of B. holmesii by the IS481  PCR had minimal diagnostic
relevance in the Alberta population during the time period of our study. The IS481 PCR assay is
now used in our laboratory routinely for front-line screening of samples for B. pertussis with
associated enhancement in diagnostic sensitivity compared with DFA and culture. Retrospectively,
patients' samples are batched and tested by the IS1001 MB and TPR assays for research purposes
and to ensure there is no change in B. holmesii incidence in the population.
Background
The etiologic agent of whooping cough is Bordetella pertus-
sis. Diagnosis at an early stage of illness is desired to insti-
tute therapy and prevent transmission. Pertussis-like
respiratory illness can also be caused by other Bordetella
species including parapertussis [1], bronchiseptica [2] and
holmesii [3,4]. Currently available B. pertussis diagnostic
methods include culture, direct fluorescent antigen (DFA)
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tests, serology and nucleic acid amplification assays such
as the polymerase chain reaction (PCR). The first publica-
tion of B. pertussis PCR was in 1989 [5]. Since then numer-
ous protocols have been reported targeting different
bacterial genes. B. pertussis PCR can be applied directly to
nasopharyngeal specimens, is more sensitive than culture,
can detect nonviable organisms and results using this
method can be obtained rapidly. Thus, this diagnostic
approach has the potential to improve our understanding
of B. pertussis transmission and epidemiology, to allow us
to measure accurately the impact on the community, as
well as enhance studies of vaccine efficacy.
B. pertussis carries 50–100 copies of IS481 and therefore
this should be a good target for development of a sensitive
diagnostic assay when compared with other single-copy
regions or genes. Indeed, IS481-based PCR has been
shown to be more sensitive than one designed against the
toxin promoter [6]. It has been shown that PCR assays tar-
geting IS481 PCR are highly specific for B. pertussis and B.
holmesii  [7] and, in a real-time format, this approach
enhances diagnostic utility above other methods. How-
ever, the potential detection of B. holmesii in cases of a per-
tussis-like illness could compromise appropriate
management and compromise studies of vaccine efficacy
[7].
In this study we aimed to assess the diagnostic utility of an
IS481 real-time PCR assay [7], compare the PCR results to
culture and DFA, assess the incidence of B. holmesii in the
test population and develop and apply a novel real-time
PCR assay against the toxin promoter region for specific
detection (and thus confirmation) of B. pertussis infection.
Methods
Bacterial strains
All bacteria used for the study were from standard cultures
grown at 35°C in ambient atmosphere on Regan-Lowe
media (Daylnn Biologicals Inc., Calgary, AB). B. pertussis,
B. holmesii, B. bronchiseptica and B. parapertussis cultures
were suspended in sterile saline at a concentration equiv-
alent to 108 cfu/ml, based on McFarland turbidimetric
standards.
Processing of specimens
Consecutive nasopharyngeal (NP) specimens received
during 2003 (n = 204) and 2004 (n = 604) for B. pertussis
DFA and culture testing were used for the PCR validation
study. These specimens were collected and submitted
from clinics across Southern Alberta to the Provincial Lab-
oratory for Public Health (ProvLab; Calgary, AB). Clinical
data were not collected. Dacron NP swabs (Oxoid Inc.,
Nepean, ON) were received in either charcoal (Copan
Diagnostics Inc., Corona, CA; 88 % of the specimens) or
Regan-Lowe (Daylnn Biologicals Inc., Calgary, AB; 12 %
of the specimens) transport media. The Regan Lowe
medium contained cephalexin which would inhibit B.
holmesii and prevent its identification by culture. Swabs
were placed into 50 µl of 1 % (w/v) casamino acid (Difco,
Becton Dickison, Sparks, MD) diluted in PBS. The wire
from the NP swab was cut and then, after brief vortexing
to remove cellular material into the fluid, the swab was
removed. The casamino acid volume was split for bacteri-
ology (DFA/culture) and molecular testing (PCR). If a
DFA slide was submitted in addition to the NP swab 20 µl
of the swab/casamino acid was used each for culture and
PCR. If a DFA slide was not received with the patient swab,
the casamino acid was split and 10 µl of the swab/
casamino acid was used each for DFA, culture and PCR.
Whether a slide for DFA was submitted or not, the volume
of sample used for analysis by PCR or culture was always
the same.
DFA
DFA testing was performed using a commercial mono-
clonal antibody reagent, according to the manufacturer's
instructions (Accu-MAb™ Plus, Altachem Pharma Inc.,
Edmonton, AB).
Culture
For culture, the 10 or 20 µl of patient specimen was made
up to 200 µl with 1% casamino acid and split equally
between two Regan-Lowe plates, one with and one with-
out cephalexin (Daylnn). Cultures were held for 7 days
and inspected daily. Opalescent colonies were gram
stained. If gram negative rods or coccobacilli were seen a
suspension of colony was prepared for identification
using the fluorescein conjugated monoclonal antibody
above.
DNA extraction
Nucleic acid was extracted from bacterial suspensions and
clinical specimens using the automated MagNa Pure LC™
and DNA Isolation Kit I (Roche Diagnostics, Laval, QC).
The 10 or 20 µl of patient specimen was made up to 200
µl with physiological saline prior to extraction and elution
was into 100 µl volume. A negative control of 200 µl
saline was included. Ten µl of a B. pertussis control (ATCC
9797 at 106 cfu/ml) was made up to 200 µl with saline
and used as a positive extraction control.
Primers and probes
The primers used in all assays were prepared by the Uni-
versity of Calgary Core DNA Synthesis facility. The probes
used in all assays were prepared by Applied BioSystems
(Foster City, CA).
IS481 Hybridization probe assay
Primers and probes used in the IS481 hybridization probe
(IS481 HP) assay are as described previously [7]. Real-BMC Infectious Diseases 2006, 6:62 http://www.biomedcentral.com/1471-2334/6/62
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Alignment based on B. pertussis ATCC 9797 with primers and probe for real-time PCR indicated Figure 1
Alignment based on B. pertussis ATCC 9797 with primers and probe for real-time PCR indicated. The selected 
forward primer is labeled box 1 (base pairs 51–69) the reverse primer as box 2 (base pairs 218–199) and the probe by box 3 
(base pairs 73–89). GenBank accession numbers for each isolate as listed in order above are AF157344, AF157363, AF157362, 
AF157364, AF157347, AF157357, AF157361, respectively.
                             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 5          15         25         35         45         55       
B.pertussis ATCC 9797        CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGCAT GCGTGCAGAT  
B.bronchiseptica AB 1254     CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
B.bronchiseptica ATCC 786    CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
B.bronchiseptica ATCC 19395  CGTCCGGCTG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
B.parapertussis KP92\83\93   CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
B.parapertussis KP92\437\93  CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
B.parapertussis ATCC 15311   CGTCCGGCCG GCACCATCCC GCATACGTGT TGGCAACCGC CAACGCGTAT GCGCGCGGAT  
                             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                 65         75         85         95        105        115       
B.pertussis ATCC 9797        TCG------- ---TCGTACA AAACCCTCGA TTCTTCCGTA CATCCCGCTA CTGCAATCCA  
B.bronchiseptica AB 1254     GCG------- ---TCGCACA AAGCCCTCGA TTCTTCCGCA CATCCCGCTA CTGCAATCCA  
B.bronchiseptica ATCC 786    GCG------- ---TCGCACA AAGCCCTCGA TTCTTCCGCA CATCCCGCTA CTGCAATCCA  
B.bronchiseptica ATCC 19395  GCGCGCGGAT GCGTCGCACA AAGCCCTCGA TCCTTCCGCA CATCCCGCTA CTGCAATCCA  
B.parapertussis KP92\83\93   GCGCGCGGAT GCGTCGCACA AAGCCCTCAA TCCTTCCGCA CATCCCGCTA CTGTAATCCA  
B.parapertussis KP92\437\93  GCGCGCGGAT GCGTCGCACA AAGCCCTCAA TCCTTCCGCA CATCCCGCTA CTGTAATCCA  
B.parapertussis ATCC 15311   GCGCGCGGAT GCGTCGCACA AAGCCCTCAA TCCTTCCGCA CATCCCGCTA CTGTAATCCA  
                             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                125        135        145        155        165        175       
B.pertussis ATCC 9797        ACACGGCATG AACGCTCCTT CGGCGCAAAG TCGCGCGATG GTACCGGTCA CCGTCCGGAC  
B.bronchiseptica AB 1254     ACACGGCGCG AACGCTCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCAGAC  
B.bronchiseptica ATCC 786    ACACGGCGCG AACGCTCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCAGAC  
B.bronchiseptica ATCC 19395  ACACGGCGCG AACGCCCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCGGAC  
B.parapertussis KP92\83\93   ACACGGCGCA AACGCCCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCGGAC  
B.parapertussis KP92\437\93  ACACGGCGCA AACGCCCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCGGAC  
B.parapertussis ATCC 15311   ACACGGCGCA AACGCCCCTT CGGCGCAAAG TCGCACGATG GTACCGGTCG CCGTCCGGAC  
                             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                                185        195        205        215        225        235       
B.pertussis ATCC 9797        CGTGCTGACC CCCCTGCCAT GGTGTGATCC GTAAAATAGG CACCATCAAA ACGCAGAGGG  
B.bronchiseptica AB 1254     TGTGCCGACC CCCCTGCCAT GGTGTGATCC GCAAAATAGG CGCCACCGAA ACGCAGAGGG  
B.bronchiseptica ATCC 786    TGTGCCGACC CCCCTGCCAT GGTGTGATCC GCAAAATAGG CGCCACCGAA ACGCAGAGGG  
B.bronchiseptica ATCC 19395  CGTGCCGACC CCCCTGCCAT GGTGTGATCC GCACAATAGG CACCACGGAA ACGCAGAGGG  
B.parapertussis KP92\83\93   CGTGCCGACC CCCCTGCCAT GGTGTGATCC GCAAAATAGG CGCCACAGAA ACGCAGAGGG  
B.parapertussis KP92\437\93  CGTGCCGACC CCCCTGCCAT GGTGTGATCC GCAAAATAGG CGCCACAGAA ACGCAGAGGG  
B.parapertussis ATCC 15311   CGTGCCGACC CCCCTGCCAT GGTGTGATCC GCAAAATAGG CGCCACAGAA ACGCAGAGGG  
                             ....|.... 
                                245  
B.pertussis ATCC 9797        GAAGACGGG 
B.bronchiseptica AB 1254     GAAGACGGG 
B.bronchiseptica ATCC 786    GAAGACGGG 
B.bronchiseptica ATCC 19395  GAAGACGGA 
B.parapertussis KP92\83\93   GAAGACGGA 
B.parapertussis KP92\437\93  GAAGACGGA 
B.parapertussis ATCC 15311   GAAGACGGA 
1 
3 
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time PCR was performed in a 20 µl reaction mixture with
final concentrations of 1X LightCycler™ FastStart DNA
master hybridization probes mix (Roche Diagnostics), 3
mM MgCl2, 0.5 µM of each primer, 0.2 µM of each hybrid-
ization probe and 5 µl of extracted template DNA. The
amplification profile consisted of activation of enzyme at
95°C for 10 min followed by 50 cycles consisting of heat-
ing at 20°C/s to 95°C with a 10s hold, cooling at 20°C/s
to 50°C with a 10s hold and heating at 20°C/s to 72°C
with a 10s hold. Single fluorescent readings were taken at
the annealing temperature (55 °C, once per cycle). Ampli-
fication, detection and data analysis were performed on
the LightCycler™ 2.0 with software version 4.0 (Roche
Diagnostics).
IS481 and IS1001 molecular beacon assays
Primers and molecular beacons used in the IS481 and
IS1001  molecular beacon (MB) assays are previously
described [8]. The IS481 MB assay targets the IS481 region
for detection of B. pertussis and B. holmesii and the IS1001
MB assay targets the IS1001 region for detection of B. par-
apertussis and B. holmesii.
These assays were originally designed for the iCycler (Bio-
Rad, Hercules, CA), but the assays were adapted for use on
the LightCycler™ for the purposes of this study. Initial
optimization involved testing a range of MgCl2 concentra-
tions and varying annealing temperatures and cycling
times in the amplification profile, using serial dilutions of
purified  B. pertussis (ATCC 9797), B. holmesii (ATCC
51541) and B. parapertussis (ATCC 1533) DNA.
The optimized IS481 MB assay was performed in a 20 µl
of reaction mixture with final concentrations of 1X Light-
Cycler™ FastStart DNA master hybridization probes mix, 3
mM MgCl2, 0.1 µM of each primer, 0.3 µM of the IS481
molecular beacon and 5 µl of extracted template DNA.
The optimized IS1001 MB assay was performed in 20 µl of
reaction mixture with final concentrations of 1X LightCy-
cler™ FastStart DNA master hybridization probes mix, 4.5
mM MgCl2, 0.2 µM of each primer, 0.4 µM of the IS1001
molecular beacon and 5 µl of extracted template DNA.
The amplification profile for both assays consisted of acti-
vation of enzyme at 95°C for 10 min followed by 50
cycles consisting of heating at 20°C/s to 95°C with a 5 s
hold, cooling at 20°C/s to 55°C with a 20 s hold, and
heating at 10°C/s to 72°C with a 15 s hold. Single fluores-
cent readings were taken at the annealing temperature
(55°C, once per cycle). Amplification, detection and data
analysis were performed on the LightCycler™ 2.0 with
software version 4.0.
Development of a novel toxin promoter region (TPR) 
hydrolysis probe assay
Selected sequences of the toxin promoter gene of B. pertus-
sis with 100% homology in a 239 bp region were obtained
from GenBank (accession numbers AF157344,
AF157344, AF157332, AF157342, AF157341, AF157340,
AF157337), aligned and a consensus sequence deter-
mined (BioEdit, version 7.0.1, Isis Pharmaceuticals Inc.,
Carlsbad, CA). This consensus was then aligned with 3
different strains of B. parapertussis and B. bronchiseptica to
determine significant polymorphic regions (Figure 1).
Primers and a probe were designed from the B. pertussis
consensus sequence using PrimerExpress software
(Applied BioSystems, Foster City, CA) with some adapta-
tions to incorporate the polymorphic regions. The probe
was designed with a FAM fluorescent reporter on the 5'
end and non-fluorescent black hole quencher (BNFQ) at
the 3' end. PrimerExpress was used to ensure minimal
self-complementary and secondary structures for primers
and probe. A BLAST search of available sequences in the
GenBank database was performed to verify the specificity
of the primers and probe. Several primer pairs were tested
by conventional PCR to determine the combination of
forward and reverse primers that performed optimally.
The primer pair that was finally chosen for conventional
and real-time PCR amplified a 167 bp region. Sequences
of optimized primers and hydrolysis probe were as fol-
lows:
Forward TPR primer 5'GCGTGCAGATTCGTCGTAC3'
Reverse TPR primer 5'TGATGGTGCCTATTTTACGG3'
Hydrolysis (TaqMan) TPR probe 5'FAM-ACCCTCGAT-
TCTTCCGT-BNFQ3'
Conventional PCR was performed in 50 µl of reaction
mixture with final concentrations of 1X PCR buffer (Invit-
rogen Canada Inc., Burlington, ON), 2 mM MgCl2, 0.1
mM of each dNTP (Invitrogen), 0.4 µM of each primer,
1.25 U of DNA Taq polymerase (Invitrogen) and 5 µl of
extracted template DNA. The amplification profile con-
sisted of an initial incubation of 3 min at 95°C followed
by 40 cycles of 30 s at 95°C, 30 s at 55°C and 30 s at
72°C, with a final 10 min hold at 72°C. The 167 bp B. per-
tussis product was separated by agarose gel electrophoresis
(2 % agarose containing 0.5 µg/ml ethidium bromide in
0.5 × TBE buffer). Amplified products were viewed and
photographed under UV light.
The real-time TPR assay was performed on the LightCy-
cler™ with a variety of MgCl2, primers and probe concen-
trations. The optimized reaction was undertaken in a 20
µl reaction mixture with final concentrations of 1X Light-
Cycler FastStart DNA master hybridization probes mix, 3BMC Infectious Diseases 2006, 6:62 http://www.biomedcentral.com/1471-2334/6/62
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mM MgCl2, 0.5 µM each primer, 0.1 µM probe, and 5 µl
of extracted template DNA. The amplification profile con-
sisted of activation of enzyme at 95°C for 10 min fol-
lowed by 50 cycles consisting of heating at 20°C/s to
95°C with a 5 s hold, cooling at 20°C/s to 55°C with a 20
s hold and heating at 10°C/s to 72°C with a 15 s hold.
Single fluorescent readings were taken at the annealing
temperature (55°C, once per cycle). Amplification, detec-
tion and data analysis were performed on the LightCy-
cler™ 2.0 with software version 4.0.
Reporting of results and data analysis
For this laboratory based study a positive result for any
PCR or culture-based assay was considered a "true posi-
tive" for analysis. Only conventional DFA and culture
were reported to submitting physicians during this study
period.
Results
Analytical sensitivity and specificity of the IS481 HP assay
The IS481 HP assay was performed on a serial dilution of
purified DNA of B. pertussis ATCC 9797 to determine the
limit of detection for this assay. This assay gave a good
positive signal from 10 cfu/ml stock reproducibly (equiv-
alent to 0.1 cfu input into the assay; Figure 2). The 1 cfu/
ml stock (input 0.01 cfu/ml) gave a positive result in
approximately 20% of tests. The same positive control
stock preparation was used as the processed positive con-
trol in the validation study, at 5000 cfu/ml and had an
average Ct value of 26.0 (± 2.0) cycles. This corresponds
LightCycler™ amplification profile of the IS481 HP probe assay with a dilution series of B. pertussis Figure 2
LightCycler™ amplification profile of the IS481 HP probe assay with a dilution series of B. pertussis ATCC 9797 
strain of B. pertussis was utilized (106 cfu/ml to 10-3 cfu/ml). Analytical sensitivity of this assay is 10 cfu/ml (0.1 cfu input). The 
dashed lines correspond to the average Ct value where conventional results are: 1 = DFA positive and culture positive, 2 = 
DFA negative, culture positive, 3 = DFA negative, culture negative. HP = hybridization probe, Ct = crossing threshold, DFA = 
direct fluorescent antigen
2 3 1BMC Infectious Diseases 2006, 6:62 http://www.biomedcentral.com/1471-2334/6/62
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to an inter-assay coefficient of variation of approximately
8 % for this control. As expected, this assay picked up B.
holmesii as well as B. pertussis but not B. parapertussis [7].
Further assessment of specificity for this assay was not
undertaken but has been evaluated elsewhere [7].
Comparison of the IS481 HP assay with conventional 
methods
A total of 808 specimens were tested by PCR for B. pertussis
during this study between March 2003 and April 2004
(204 specimens from 2003 and 604 from 2004). Figure 3
summarizes the results and Table 1 shows the average
crossing threshold (Ct) and standard deviation (SD) for
positive specimens for each combination of results.
Of the 808 samples tested, 729 were negative by all 3
methods. Nine contained detectable IS481 target DNA in
a single run but results were not reproducible and finally
were reported as not containing detectable B. pertussis.
These specimens were weakly positive [average Ct of 38.1
(± 2.3) cycles]. DFA had poor sensitivity, missing 17 sam-
ples that were positive by both culture and the IS481 HP
assay, as well as 28 samples that were positive by the IS481
HP assay, but negative by culture. Six specimens that were
DFA positive, tested negative by both culture and PCR and
are most likely false positives due to the subjective nature
of DFA interpretation. Seven specimens were overgrown
in culture, 4 of which were negative by PCR and DFA and
3 were positive by PCR (1 of these 3 was positive by DFA).
Comparison of real-time PCR methods for the detection of 
B. pertussis and B. holmesii
The analytical sensitivity of the IS481 MB assay was deter-
mined using a serial dilution of purified DNA of B. pertus-
sis ATCC 9797 with a detection limit of 10 cfu/ml (1 cfu
input) which is similar to that reported previously [8].
Thus a 10-fold difference in end point sensitivity was
noted when compared with the IS481 HP assay. The IS481
MB assay gave average Ct values 4–5 cycles higher for pos-
itive patient specimens than the IS481 HP assay (Table 1).
The IS481 MB and IS1001 MB assays [8] utilize primers
and probes that amplify and detect a 154 bp fragment in
the IS481 region specific to B. pertussis and B. holmesii (Fig-
ure 4) and a 186 bp region in the IS1001 region, specific
to B. parapertussis and B. holmesii (Figure 5), respectively.
Combined results from both reactions can resolve
whether a specimen is positive for B. pertussis, B. paraper-
tussis or B. holmesii. In our experiments, the IS1001 prim-
ers gave a non-specific product of approximately 700 bp
for two B. bronchiseptica strains, but this product was not
recognized by the MB probe (Figure 5). Further assess-
ment of specificity for this assay was not undertaken dur-
ing this study but has been evaluated elsewhere [8].
Several previously extracted patient samples were retested
by the IS481  HP assay to ensure the integrity of the
extracted DNA over time (data not shown). Eleven posi-
tive specimens with an average Ct value of 25.2 (± 4.8)
cycles on the original PCR run, remained positive with an
average Ct value of 25.9 (± 5.1). This difference was con-
sidered insignificant, indicating that the DNA in these
specimens had not degraded over time, and that subse-
quent retesting with the IS481 MB and IS1001 MB assays
for comparison was valid.
All 66 samples positive by the IS481  HP assay were
retested by both the IS481 MB and IS1001 MB assays.
Table 1 compares these 66 specimens in relation to PCR
and conventional results, including average Ct values (±
SD). Sixty-four of 66 (93.0%) of these samples confirmed
positive for B. pertussis by the IS481 MB assay. The 2 sam-
ples that did not confirm were weak positives as they were
also missed by both DFA and culture and had high Ct val-
ues on the IS481 HP assay (39.7and 39.1 cycles). No B.
holmesii was detected in this population by the IS1001 MB
assay. A random selection of 29 samples that were nega-
tive by the IS481 HP assay were also screened by the IS481
and IS1001 MB assays. No further positives were obtained
Correlation of positive results for specimens tested by DFA,  culture and the IS481 HP PCR assay for B. pertussis Figure 3
Correlation of positive results for specimens tested 
by DFA, culture and the IS481 HP PCR assay for B. 
pertussisw HP = hybridization probe, DFA = direct fluores-
cent antigen Seven specimens were overgrown in culture and 
thus have not been included in the Figure (see text for 
details).
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Table 1: Comparison of positive B. pertussis patient specimens by real-time RT-PCR assays Average crossing threshold (Ct) values and standard deviations (SD) for each 
combination of PCR and conventional results are shown. Samples were selected based on results for DFA/culture IS481 HP PCR.
Result 
combination
IS481 HP Assay IS481 MB Assay* TPR Assay*
Positive/
tested (%)
Average Ct of 
positives
SD of positives Positive/
tested (%)
Average Ct of 
positives
SD of positives Positive/
tested (%)
Average Ct of 
positives
SD of positives
DFA negative 
Culture negative 
Screen PCR 
(IS481HP) positive
28/28 (100.0) 35.7 3.9 26/28 (92.9) 40.4 3.2 15/28 (53.6) 40.1 2.1
DFA negative 
Culture positive 
Screen PCR 
(IS481HP) positive
17/17 (100.0) 31.6 5.4 17/17 (100.0) 36.5 5.7 15/17 (88.2) 37.7 5.0
DFA positive 
Culture positive 
Screen PCR 
(IS481HP) positive
21/21 (100.0) 24.9 3.8 21/21 (100.0) 30.1 3.9 21/21 (100.0) 32.3 3.4
*In cases where cycle results were >45, 45 was used to calculate average Ct values and SD. HP = hybridization probe, MB = molecular beacon, TPR = toxin promoter region, DFA = direct 
fluorescent antigen.BMC Infectious Diseases 2006, 6:62 http://www.biomedcentral.com/1471-2334/6/62
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by the IS481 MB assay but 2 specimens that were culture
positive for B. parapertussis were detected by the IS1001
MB assay, as expected.
TPR hydrolysis probe assay
This novel real-time PCR assay showed high specificity for
B. pertussis and did not pick up cultured B. holmesii, B.
bronchiseptica or B. parapertussis (Figure 6). Analytical sen-
sitivity of this assay was performed on a serial dilution of
purified DNA of B. pertussis ATCC 9797 and detected 100
cfu/ml, a 10–100 -fold difference from the IS481 HP and
IS481 MB assays. No difference in limit of detection was
noted whether analysis of amplified products was by aga-
rose gel electrophoresis or using the TPR probe. Thus the
difference in sensitivity when comparing this assay to
those targeting insertion sequences was more likely
related to the difference in template copy number than
design of the probe. The conventional assays targeting
TPR (used in the developmental stages of the final real-
time assay) gave the same limit of detection when ana-
lysed by agarose gel electophoresis as products from the
LightCycler™ assay (1000 cfu/ml stock concentration or
10 cfu input into the assay). Interestingly, one of the B.
holmesii isolates gave two higher molecular weight bands
than the expected specific product when analyzed by aga-
rose gel electrophoresis (lane 13 from gel inlay of Figure
6). These products were not picked up by the specific
probe, however.
All 66 samples positive by the IS481  HP assay were
retested by the TPR assay (Table 1). The TPR assay was
able to detect 100% of the specimens where the IS481 HP
LightCycler™ amplification profile of the IS481 MB assay with Bordetella isolates Figure 4
LightCycler™ amplification profile of the IS481 MB assay with Bordetella isolates The samples correspond to: 1 = B. 
bronchiseptica ATCC 10580, 2 = B. bronchiseptica ATCC 29513, 3 = B. parapertussis ATCC 1533, 4 = B. parapertussis 33047, 5 = 
B. parapertussis 33205, 6 = B. holmesii ATCC 51541, 7 = B. holmesii 98P1995-F, 8 = B. holmesii 98P0971-D, 9 = B. pertussis ATCC 
9797. The specific amplified product is 154 bp and the agarose gel of products is given as an inlay (numbers correspond to sam-
ples in the amplification curves). Stocks of Bordetella isolates were approximately 106cfu/ml unless otherwise quoted. MB = 
molecular beacon
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assay, IS481 MB assay, culture and DFA were all positive.
The sensitivity of this assay decreased slightly where DFA
was unable to detect positives. Sensitivity was 50% for
specimens which were culture negative but IS481  HP
assay positive.
Patient data collected after this study (June to October
2004) remained consistent with the results presented
above (data not shown). B. pertussis was detected in
approximately 10% of the specimens and B. holmesii was
absent (using the IS1001 MB assay). Of the 16 positive
specimens detected by the IS481 HP assay (from a total of
131 tested), all were detected by the IS481 MB assay, and
12 were detected by the TPR assay. The 4 positives that the
TPR assay missed were weak positives with high Ct values
on the IS481 HP and IS481 MB assays.
Discussion
PCR has been shown to be more sensitive than culture,
resulting in culture negative/PCR positive specimens [2,9-
14]. Only a few studies have reported cases of culture pos-
itive/PCR negative samples and most of these were earlier
papers with interpretation of results complicated by the
following factors: unequal sample splitting, lack of DNA
extraction procedures, inhibited PCR reactions and/or
lack of sensitive product detection methods.
Real-time PCR assays with IS481 have been published [6-
8,15-18]. Advantages offered by real-time PCR include;
elimination of post-amplification handling thereby
reducing the risk of contamination, faster turn-around
time and higher sensitivity [8]. We were able to confirm in
this study the diagnostic utility of the previously pub-
lished methods, adapt alternative assays targeting inser-
LightCycler™ amplification profile of the IS1001 MB assay with Bordetella isolates Figure 5
LightCycler™ amplification profile of the IS1001 MB assay with Bordetella isolates The samples correspond to: 1 = 
B. bronchiseptica ATCC 10580, 2 = B. bronchiseptica ATCC 29513, 3 = B. parapertussis ATCC 1533, 4 = B. parapertussis 33047, 5 
= B. parapertussis 33205, 6 = B. holmesii ATCC 51541, 7 = B. holmesii 98P1995-F, 8 = B. holmesii 98P0971-D, 9 = B. pertussis 
ATCC 9797. The specific amplified product is 186 bp and the agarose gel of products is given as an inlay (numbers correspond 
to samples in the amplification curves). MB = molecular beacon.
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tion sequences to rapid LightCycler™ format for
confirmation of positive results, as well as design and
develop an assay based on TPR for B. pertussis. In our
study, the IS481 HP assay increased the yield of B. pertussis
positive nasopharyngeal swabs by 1.7 fold (detecting 28
positives in addition to the 38 detected with culture).
None of the specimens were culture positive/PCR nega-
tive. The IS481 HP and IS481 MB assays had analytical
sensitivities of 1–10 cfu/ml (0.1–1 cfu input), which is
consistent with previously published data [8].
A problem that we encountered with the IS481 HP assay
was weak positives with high crossing thresholds ("high
cycle positives") that were irreproducible with a second
run of the same IS481 HP assay and/or with the IS481 MB
assay. These were reported as not containing detectable
pertussis DNA. It is unknown whether this type of result
represents very low levels of B. pertussis in the specimen or
a false positive signal.
One concern is that culture negative/PCR positive speci-
mens may represent false positive PCR reactions rather
than increased PCR sensitivity. As a first check for possible
false positive reactions, we utilized assays targeting differ-
ent regions of IS481 (the IS481 HP and IS481 MB assays)
with good concordance for positive results. A further
approach we used to help interpret IS481 positive results
was to perform PCR against a different target gene (toxin
LightCycler™ amplification profile of the TPR assay with Bordetella isolates Figure 6
LightCycler™ amplification profile of the TPR assay with Bordetella isolates. The samples correspond to: 1–8 = 
dilution series of B. pertussis ATCC 9797 (108cfu/ml to 101cfu/ml, respectively), 9 = B. bronchiseptica ATCC 10580, 10 = B. bron-
chiseptica ATCC 29513, 11 = B. parapertussis ATCC 1533, 12 = B. parapertussis 33047, 13 = B. holmesii ATCC 51541, 14 = B. 
holmseii 98P1995. The amplified product is 167 bp and the agarose gel of products is given as an inlay (numbers corresponding 
to samples in the amplification curves). Stocks of Bordetella isolates were approximately 106cfu/ml unless otherwise quoted.
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promoter). If both gene target assays (against IS481 and
toxin promoter) are positive, then it is reasonable to con-
clude that the specimen is truly B. pertussis positive. We
developed a novel real-time PCR targeting the TPR for use
as a second target to IS481. Currently there is no sequence
available in GenBank for the TPR of B. holmesii, which pre-
sented a challenge in developing this assay. However, due
to the sequence heterogeneity among other Bordetella spe-
cies, we were able to design a highly B. pertussis-specific
assay. We tested the specificity of the toxin promoter
primers with isolates of B. parapertussis, B. bronchiseptica
and B. holmesii. Even large amounts of DNA from these
organisms failed to give false positive results using this
assay. The TPR PCR had an analytical sensitivity of 1000
cfu/ml (10 cfu input) and is thus less sensitive than the
assays targeting the IS481  region. This is in agreement
with previous data [6] and is explained by the gene copy
number of 50–100 for IS481 compared to 1 for the toxin
promoter. We recognized that sensitivity would be a lim-
iting factor of the toxin promoter target. Among the 66
specimens that were positive by the IS481 HP assay, there
were 51 that also gave positive results with the TPR PCR.
Of the 15 that did not confirm, 2 were culture positive and
therefore represent false negatives with the TPR assay,
which could possibly be due its poorer sensitivity or due
to a polymorphism of the toxin promoter [19]. Thus, even
with its 100 fold-lower analytical sensitivity, the TPR PCR
was useful for confirming the majority of specimens.
The IS481 target for B. pertussis diagnosis has the limita-
tion of also being present in B. holmesii [7,13,20] and
some B. bronchiseptica strains (ATCC 4617, ATCC 14455)
[9]. The IS481 sequence of B. holmesii and B. pertussis dif-
fers by only 2 bases [7]. One approach to decipher
whether a specimen positive for IS481 is B. pertussis versus
B. holmesii is to perform the IS1001 MB assay [8]. B holm-
esii contains the IS1001 but B. pertussis does not. B holmesii
was not detected in any of our NP specimens, which sug-
gests that it may not be unnecessary to rule out B. holmesii
for specimens that are positive for IS481 in the Alberta
population. Our study did not include B. bronchiseptica
ATCC 4617 or ATCC 14455 but this warrants further
study. Interestingly, the IS1001 primers gave a product for
B. bronchiseptica ATCC 29513 and ATCC 10580, which has
not been previously reported. This product was not recog-
nized by the MB probe, demonstrating the specificity pro-
vided by the probe.
Although PCR is a useful tool for B. pertussis diagnosis, it
is still important to obtain isolated B. pertussis organisms
for epidemiologic characterization. We found that both
culture and PCR could be undertaken from a single NP
swab. Elution of the swab in casamino acid allowed equal
splitting of the specimen for DFA or culture and PCR,
thereby removing sampling bias in the interpretation of
results.
Conclusion
In summary, the results of this study confirm that PCR is
more sensitive than culture and DFA for diagnosis of B.
pertussis. As a result of this work our laboratory has discon-
tinued DFA and reports only IS481 HP PCR results to sub-
mitters. Specificity of reproducible positive specimens is
100% and B. holmesii is not prevalent in our population.
We have been able to show that PCR is a suitable and
practical approach to B. pertussis detection and diagnosis,
providing rapid results, which are useful for management
of individuals and potential outbreaks. We have explored
use of additional tests in order to differentiate B. pertussis
from closely related organisms, which may present with
similar symptoms. Currently, all NP swabs are tested
using the IS481 HP assay, and positive specimens are cul-
tured. The IS481 MB assay is employed for specimens that
are difficult to resolve using the IS481 HP assay and as a
second line test. Retrospectively, patient samples are
batched and tested by the IS1001 MB and TPR assays for
research purposes and to ensure there are no changes in B.
holmesii incidence in the population. The screening PCR
assay is more sensitive than the other procedures, and its
specificity is acceptable. Culture is maintained for PCR-
positive specimens only, for epidemiologic purposes. Our
follow up procedures confirm the validity of the front-line
PCR test for B. pertussis in our laboratory.
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